Parallel Advisors’s Inari Medical, Inc. Common Stock NARI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-52,441
Closed -$2.68M 3713
2024
Q4
$2.68M Buy
52,441
+23
+0% +$1.13K 0.06% 219
2024
Q3
$2.16M Buy
52,418
+2
+0% +$96 0.05% 232
2024
Q2
$2.52M Sell
52,416
-80
-0.2% -$3.55K 0.06% 212
2024
Q1
$2.52M Sell
52,496
-27
-0.1% -$1.44K 0.07% 204
2023
Q4
$3.41M Buy
52,523
+827
+2% +$49.8K 0.1% 152
2023
Q3
$3.38M Buy
51,696
+1,313
+3% +$82.6K 0.11% 146
2023
Q2
$2.93M Sell
50,383
-23
-0% -$1.45K 0.09% 164
2023
Q1
$3.11M Sell
50,406
-93
-0.2% -$5.58K 0.1% 156
2022
Q4
$3.21M Sell
50,499
-19
-0% -$1.38K 0.14% 113
2022
Q3
$3.67M Buy
50,518
+10
+0% +$745 0.17% 91
2022
Q2
$3.43M Buy
50,508
+128
+0.3% +$9.2K 0.16% 95
2022
Q1
$4.57M Buy
50,380
+28
+0.1% +$2.29K 0.18% 85
2021
Q4
$4.6M Hold
50,352
0.17% 96
2021
Q3
$4.08M Hold
50,352
0.16% 101
2021
Q2
$4.7M Hold
50,352
0.2% 81
2021
Q1
$5.39M Sell
50,352
-9,500
-16% -$986K 0.25% 70
2020
Q4
$5.22M Buy
+59,852
New +$4.23M 0.28% 63

Other funds holding NARI

Parallel Advisors's NARI Position: Q1 2025 in Review

Parallel Advisors sold out of Inari Medical, Inc. Common Stock (NARI) in Q1 2025, closing a stake of 52,441 shares — an estimated $2.68M sold.

Parallel Advisors first reported a position in NARI in Q4 2020 and held it in 17 quarters. The position peaked at $5.39M in Q1 2021. 4 funds tracked by Wall St. Rank hold NARI as of Q1 2025.

  • Parallel Advisors reported no remaining Inari Medical, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Parallel Advisors sold 52,441 Inari Medical, Inc. Common Stock shares in Q1 2025, an estimated $2.68M.
  • Parallel Advisors first reported a position in Inari Medical, Inc. Common Stock in Q4 2020 and held it in 17 quarters.
  • Parallel Advisors's Inari Medical, Inc. Common Stock position peaked at $5.39M in Q1 2021.
  • 4 funds tracked by Wall St. Rank held Inari Medical, Inc. Common Stock as of Q1 2025.

Based on Parallel Advisors's 13F filing for Q1 2025, filed 8 Apr 2025.